Aarsland D, et al. Parkinson disease-associated cognitive impairment. Nat Rev Dis Prim. 2021;7:47.

Article  PubMed  Google Scholar 

Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron. 2003;39:889–909.

Article  CAS  PubMed  Google Scholar 

Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16:448–58.

Article  CAS  PubMed  Google Scholar 

Liu B, et al. Effects of Eldepryl on glial cell proliferation and activation in the substantia nigra and striatum in a rat model of Parkinson’s disease. Neurol Res. 2017;39:459–67.

Article  CAS  PubMed  Google Scholar 

Henchcliffe C, Severt WL. Disease modification in Parkinson’s disease. Drugs Aging. 2011;28:605–15.

Article  CAS  PubMed  Google Scholar 

Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science. 1993;260:1130–2.

Article  CAS  PubMed  Google Scholar 

Tomac A, et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature. 1995;373:335–9.

Article  CAS  PubMed  Google Scholar 

Henderson CE, et al. GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. Science. 1994;266:1062–4.

Article  CAS  PubMed  Google Scholar 

Kramer ER, Liss B. GDNF-Ret signaling in midbrain dopaminergic neurons and its implication for Parkinson disease. FEBS Lett. 2015;589:3760–72.

Article  CAS  PubMed  Google Scholar 

Emborg ME, et al. Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF. Neurobiol Dis. 2009;36:303–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kells AP, et al. Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF. J Neurosci. 2010;30:9567–9577.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Migliore MM, et al. Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson’s disease. Neuroscience. 2014;274:11–23.

Article  CAS  PubMed  Google Scholar 

Manfredsson FP, et al. The future of GDNF in Parkinson’s disease. Front Aging Neurosci. 2020;12:593572.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tereshchenko J, Maddalena A, Bahr M, Kugler S. Pharmacologically controlled, discontinuous GDNF gene therapy restores motor function in a rat model of Parkinson’s disease. Neurobiol Dis. 2014;65:35–42.

Article  CAS  PubMed  Google Scholar 

Gill SS, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med. 2003;9:589–95.

Article  CAS  PubMed  Google Scholar 

Love S, et al. Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat Med. 2005;11:703–4.

Article  CAS  PubMed  Google Scholar 

Patel NK, et al. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann Neurol. 2005;57:298–302.

Article  CAS  PubMed  Google Scholar 

Slevin JT, et al. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg. 2005;102:216–22.

Article  CAS  PubMed  Google Scholar 

Kordower JH, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson’s disease. Science. 2000;290:767–73.

Article  CAS  PubMed  Google Scholar 

Georgievska B, Kirik D, Rosenblad C, Lundberg C, Bjorklund A. Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. Neuroreport. 2002;13:75–82.

Article  CAS  PubMed  Google Scholar 

Bauer M, et al. Lipid-mediated glial cell line-derived neurotrophic factor gene transfer to cultured porcine ventral mesencephalic tissue. Exp Neurol. 2002;177:40–9.

Article  CAS  PubMed  Google Scholar 

Chtarto A, et al. Controlled delivery of glial cell line-derived neurotrophic factor by a single tetracycline-inducible AAV vector. Exp Neurol. 2007;204:387–99.

Article  CAS  PubMed  Google Scholar 

Wang L, et al. Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson’s disease. Gene Ther. 2002;9:381–9.

Article  CAS  PubMed  Google Scholar 

McGrath J, et al. Adeno-associated viral delivery of GDNF promotes recovery of dopaminergic phenotype following a unilateral 6-hydroxydopamine lesion. Cell Transpl. 2002;11:215–27.

Article  Google Scholar 

Brundin P. GDNF treatment in Parkinson’s disease: time for controlled clinical trials? Brain. 2002;125:2149–51.

Article  PubMed  Google Scholar 

Sherer TB, Fiske BK, Svendsen CN, Lang AE, Langston JW. Crossroads in GDNF therapy for Parkinson’s disease. Mov Disord. 2006;21:136–41.

Article  PubMed  Google Scholar 

Salvatore MF, et al. Point source concentration of GDNF may explain failure of phase II clinical trial. Exp Neurol. 2006;202:497–505.

Article  CAS  PubMed  Google Scholar 

Kambey PA, et al. Failure of glial cell-line derived neurotrophic factor (GDNF) in clinical trials orchestrated by reduced NR4A2 (NURR1) transcription factor in Parkinson’s disease. A systematic review. Front Aging Neurosci. 2021;13:645583.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barker RA, et al. GDNF and Parkinson’s disease: where next? a summary from a recent workshop. J Parkinsons Dis. 2020;10:875–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rosenblad C, Georgievska B, Kirik D. Long-term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system. Eur J Neurosci. 2003;17:260–70.

Article  PubMed  Google Scholar 

Georgievska B, Kirik D, Bjorklund A. Overexpression of glial cell line-derived neurotrophic factor using a lentiviral vector induces time- and dose-dependent downregulation of tyrosine hydroxylase in the intact nigrostriatal dopamine system. J Neurosci. 2004;24:6437–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barroso-Chinea P, et al. Long-term controlled GDNF over-expression reduces dopamine transporter activity without affecting tyrosine hydroxylase expression in the rat mesostriatal system. Neurobiol Dis. 2016;88:44–54.

Article  CAS  PubMed  Google Scholar 

Mesa-Infante V, Afonso-Oramas D, Salas-Hernandez J, Rodriguez-Nunez J, Barroso-Chinea P. Long-term exposure to GDNF induces dephosphorylation of Ret, AKT, and ERK1/2, and is ineffective at protecting midbrain dopaminergic neurons in cellular models of Parkinson’s disease. Mol Cell Neurosci. 2022;118:103684.

Article  CAS  PubMed  Google Scholar 

Lang AE, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol. 2006;59:459–66.

Article  CAS  PubMed  Google Scholar 

Luz M, Mohr E, Fibiger HC. GDNF-induced cerebellar toxicity: a brief review. Neurotoxicology. 2016;52:46–56.

Article  CAS  PubMed  Google Scholar 

Hovland DN Jr., et al. Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF) in rhesus monkeys. Toxicol Pathol. 2007;35:676–92.

Article  CAS  PubMed  Google Scholar 

Hoane MR, et al. Differential in vivo effects of neurturin and glial cell-line-derived neurotrophic factor. Exp Neurol. 1999;160:235–43.

Article  CAS  PubMed  Google Scholar 

Su X, et al. Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys. Hum Gene Ther. 2009;20:1627–40.

Article